Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Apellis Pharmaceuticals is seeking a talented Director, Business Intelligence (BI) for EMPAVELI in the US. This role partners with US commercial and cross-functional teams to translate sales data and market research into actionable insights that drive strategy and execution for EMPAVELI in PNH.
The ideal candidate has 10+ years in biotech/biopharma analytics, strong Excel modeling, and familiarity with Power BI; knowledge of rare diseases is a plus.
Opportunity awaits those up to the challenge of developing transformative therapies across a broad range of debilitating diseases.
We are seeking a talented and energetic Director, Business Intelligence (BI) – EMPAVELI who will play a key role in the commercialization of EMPAVELI in PNH. The Director will be accountable for partnering closely with U.S. commercial, and cross-functional teams to generate market-specific insights from sales and performance analytics and primary market research, to create integrated, actionable insights for cross-functional stakeholder groups across the organization. The ideal candidate must have significant experience working in a commercial insights and analytics position within a biotech or biopharma company, focusing on rare diseases (hematology a plus). The Director will report to the Senior Director, Business Intelligence & Commercial Operations – EMPAVELI, and is expected to drive market knowledge and insights that foster cross-functional action, shaping strategy and tactical execution for EMPAVELI in PNH in the US.
Key Responsibilities
Hybrid
Domestic retravel may be required in this role (up to 20%)
Bachelor's Degree
Apellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases.
Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.